Immutep Limited
PRRUF
Other OTC0.05
USD
- -
- -
Immutep Limited
PRRUF
(Other OTC)
Recent
price
0.05
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Immutep Limited (ASX:IMM; NASDAQ:IMMP; OTC:PRRUF), a late clinical-stage biotechnology company headquartered in Sydney, Australia, and founded in 1987, develops novel Lymphocyte-Activation Gene-3 (LAG-3) related immunotherapies targeting cancer and autoimmune diseases; its diversified portfolio features lead candidate eftilagimod alfa (efti), a first-in-class MHC Class II agonist in pivotal Phase III TACTI-004 (KEYNOTE-F91) trial combined with pembrolizumab and chemotherapy for first-line non-small cell lung cancer across more than 150 global sites in 24 countries, alongside Phase IIb TACTI-003 in head and neck squamous cell carcinoma, Phase II AIPAC-003 in metastatic breast cancer, investigator-initiated trials like EFTISARC-NEO in soft tissue sarcoma which met its primary endpoint of tumor hyalinization, INSIGHT-003 and INSIGHT-005 in various lung and urothelial cancers, IMP761 agonist antibody in Phase I for autoimmune conditions, and licensed assets such as LAG525 to Novartis and collaborations with Merck & Co., GlaxoSmithKline, Pfizer, EOC Pharma, and others. The company operates primarily in Australia, the United States, Germany, and France, serving oncology and autoimmune patient populations through clinical-stage assets focused on immune modulation to enhance anti-tumor responses or suppress dysregulated immunity. Recent developments include positive FDA feedback in August 2025 on late-stage efti paths for head and neck cancer with CPS <1 potentially via accelerated approval, enrollment completion in AIPAC-003 Phase II with data presentation at the 2025 San Antonio Breast Cancer Symposium, primary endpoint achievement and oral presentations for EFTISARC-NEO at ESMO and CTOS 2025, launch of a new investigator-initiated Phase II neoadjuvant trial in HR+/HER2- breast cancer with George Washington University, over 170 patients enrolled in TACTI-004 surpassing futility analysis thresholds, four new patents granted covering efti manufacturing and IMP761/LAG525, appointment of Stephan Winckels as permanent Chief Medical Officer in July 2025, and a strong cash position of A$109.85 million as of September 30, 2025 supporting runway into late 2026.